Delos Wealth Advisors LLC Has $397,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Delos Wealth Advisors LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 58.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,450 shares of the company’s stock after purchasing an additional 905 shares during the quarter. Delos Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $397,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of JNJ. RFG Advisory LLC grew its position in shares of Johnson & Johnson by 7.8% during the 2nd quarter. RFG Advisory LLC now owns 18,494 shares of the company’s stock worth $2,703,000 after buying an additional 1,336 shares during the period. Bridge Creek Capital Management LLC grew its position in shares of Johnson & Johnson by 2.8% in the 2nd quarter. Bridge Creek Capital Management LLC now owns 37,073 shares of the company’s stock valued at $5,419,000 after purchasing an additional 1,018 shares during the period. Andrew Hill Investment Advisors Inc. acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $789,000. AHL Investment Management Inc. grew its position in shares of Johnson & Johnson by 29.8% in the 2nd quarter. AHL Investment Management Inc. now owns 22,492 shares of the company’s stock valued at $3,287,000 after purchasing an additional 5,170 shares during the period. Finally, Ballast Inc. grew its position in shares of Johnson & Johnson by 8.9% in the 2nd quarter. Ballast Inc. now owns 22,208 shares of the company’s stock valued at $3,246,000 after purchasing an additional 1,809 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.1 %

Shares of NYSE:JNJ opened at $149.31 on Friday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The stock has a market cap of $359.48 billion, a PE ratio of 21.61, a P/E/G ratio of 2.67 and a beta of 0.51. The business has a 50 day moving average of $158.09 and a 200-day moving average of $156.38. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter in the previous year, the company posted $2.66 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. Johnson & Johnson’s payout ratio is 71.78%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research analyst reports. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Guggenheim increased their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $175.67.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.